Akihito Kawazoe
Overview
Explore the profile of Akihito Kawazoe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
3538
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koganemaru S, Koyama S, Suto F, Koga M, Inaki K, Kuwahara Y, et al.
Cancer Res Commun
. 2024 Dec;
5(1):84-93.
PMID: 39679910
This biomarker study explored HER2 expression levels and immune cell characteristics that may affect response to T-DXd using tumor tissue samples collected from clinical trial participants. The results suggest that...
2.
Tsuge A, Watanabe S, Kawazoe A, Togashi Y, Itahashi K, Masuda M, et al.
Cancer Immunol Res
. 2024 Nov;
13(2):273-285.
PMID: 39602577
Regulatory T (Treg) cells play key roles in cancer immunity by suppressing a range of antitumor immune responses and contributing to resistance to PD-1 blockade therapy. Given their critical roles...
3.
Oshima T, Yamamoto S, Kawakami H, Makino T, Kawazoe A, Masuishi T, et al.
BJC Rep
. 2024 Nov;
2(1):66.
PMID: 39516370
Background: Esophageal cancer is one of the most common types of cancer in Japan. Herein, we report the efficacy and safety of E7389-LF plus the immune checkpoint inhibitor, nivolumab, from...
4.
Jubashi A, Nakayama I, Koganemaru S, Sakamoto N, Oda S, Matsubara Y, et al.
Gastric Cancer
. 2024 Nov;
28(1):63-73.
PMID: 39487862
Background: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate targeting HER2-positive gastric cancer or gastroesophageal junction cancer (GC/GEJC). Although effective, T-DXd has notable toxicities, including interstitial lung disease (ILD). This study...
5.
Janjigian Y, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges J, et al.
N Engl J Med
. 2024 Sep;
391(14):1360-1362.
PMID: 39282917
No abstract available.
6.
Kawazoe A, Xu R, Garcia-Alfonso P, Passhak M, Teng H, Shergill A, et al.
J Clin Oncol
. 2024 Jun;
42(24):2918-2927.
PMID: 38833658
Purpose: Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib in combination with pembrolizumab improves outcomes compared with...
7.
Ghelardi F, Fuca G, Cavalli C, Shitara K, Cohen R, Ambrosini M, et al.
Dig Liver Dis
. 2024 May;
57(1):23-29.
PMID: 38772790
Background: Microsatellite instability high (MSI-H) and/or mismatch repair deficient (dMMR) status is the strongest predictive factor for immune checkpoint inhibitors (ICIs) benefit in patients with metastatic gastroesophageal cancer (mGC). Primary...
8.
Miyashita Y, Kawazoe A, Yoshino T
Gan To Kagaku Ryoho
. 2024 Mar;
51(3):245-249.
PMID: 38494801
Colorectal cancer(CRC)is one of the most commonly diagnosed cancers worldwide. Unresectable advanced, metastatic or recurrent CRC(mCRC)remains incurable for most patients. Systemic chemotherapy is standard treatment for patients with mCRC. The...
9.
Hashimoto T, Nakamura Y, Mishima S, Nakayama I, Kotani D, Kawazoe A, et al.
Cancer Sci
. 2024 Mar;
115(5):1622-1633.
PMID: 38429886
Advanced gastric and gastroesophageal junction cancers (GC/GEJCs) harbor diverse molecular signatures, highlighting the need for intricate evaluations to identify potential therapeutic targets. Although whole-transcriptome sequencing (WTS) has emerged as a...
10.
Kitagawa Y, Matsuda S, Gotoda T, Kato K, Wijnhoven B, Lordick F, et al.
Gastric Cancer
. 2024 Feb;
27(3):401-425.
PMID: 38386238
No abstract available.